Starpharma Holdings Limited (SPL) AI Stock Analysis

• Market Cap: AU$41.82M
• Dividend Yield: N/A
• Average Volume (3M): 399.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.34
• Revenue Growth: -67.07%
• EPS Growth: -47.32%
• Country: AU
• Employees: 40
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 418,224,800
• 10 Day Avg. Volume: 165,416
• 30 Day Avg. Volume: 399,290
• PEG Ratio: 0.06
• Price to Book (P/B): 1.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

Starpharma Holdings Limited's score is primarily influenced by its financial performance, which is challenged by persistent losses despite revenue growth. Technical analysis adds some positive sentiment due to short-term price trends, but valuation remains a concern due to negative earnings and lack of dividends.

Starpharma Holdings Limited Business Overview & Revenue Model

Company Description

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

How the Company Makes Money

Starpharma Holdings Limited generates revenue through the commercialization and licensing of its proprietary dendrimer-based technologies. The company earns money by developing and selling its VivaGel® products, which are used for various antiviral and antimicrobial applications, including sexual health and infection prevention. Additionally, Starpharma licenses its DEP® drug delivery platform to pharmaceutical companies, enabling them to improve the delivery and efficacy of their drugs. This licensing model often includes upfront payments, milestone payments, and royalties on product sales. Strategic partnerships and collaborations with major pharmaceutical companies also play a significant role in driving revenue, as they facilitate the development and commercialization of new products using Starpharma's technology.

Starpharma Holdings Limited Financial Statement Overview

Summary

Starpharma Holdings Limited shows significant revenue growth but continues to report negative net income and EBIT, impacting profitability. The balance sheet is moderately leveraged with strong cash reserves, while cash flow issues highlight a need for operational improvements.

Income Statement

Starpharma Holdings Limited has shown significant revenue growth with a notable increase in total revenue from the previous year. However, the company continues to report negative net income and EBIT, which impacts its profitability margins. Gross profit margin is relatively high, indicating efficient cost management in production despite overall losses.

Balance Sheet

The company's balance sheet reflects moderate leverage with a manageable debt-to-equity ratio. The equity ratio indicates a solid capital structure, though a decline in stockholders' equity raises concerns. Cash reserves are strong, providing a buffer against liabilities.

Cash Flow

Operating cash flow remains negative, highlighting cash outflows from operations. While free cash flow has improved slightly, it remains negative, which could strain liquidity. The company has managed capital expenditures well, showing discipline in investment spending.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	8.29M	2.94M	4.68M	1.80M	6.03M
Gross Profit	7.66M	1.22M	1.91M	539.50K	4.23M
EBITDA	-9.63M	-15.25M	-15.80M	-21.42M	-14.40M
Net Income	-8.16M	-15.64M	-16.15M	-19.73M	-14.68M
Balance Sheet
Total Assets	36.81M	52.09M	66.17M	73.24M	39.08M
Cash, Cash Equivalents and Short-Term Investments	23.36M	35.18M	49.92M	60.50M	30.05M
Total Debt	3.53M	8.27M	8.19M	1.17M	1.57M
Total Liabilities	8.70M	17.27M	17.78M	10.94M	7.75M
Stockholders Equity	28.12M	34.81M	48.39M	62.30M	31.33M
Cash Flow
Free Cash Flow	-7.07M	-14.15M	-14.00M	-15.05M	-10.90M
Operating Cash Flow	-6.98M	-13.53M	-13.16M	-14.81M	-10.78M
Investing Cash Flow	-89.00K	-610.00K	-836.00K	-246.00K	-125.00K
Financing Cash Flow	-4.75M	-695.00K	3.23M	46.30M	-584.00K

Starpharma Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SPL, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.09, and above the 200-day MA of 0.10, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 64.01 is Neutral, neither overbought nor oversold. The STOCH value of 90.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:SPL.

Starpharma Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥345.70B	11.08	-2.99%	2.56%	11.77%	-10.16%
PTX	56 Neutral	AU$33.82M	―	-36.95%	―	―	11.11%
SPL	47 Neutral	AU$41.82M	―	-43.63%	―	-67.07%	-47.32%
CYYNF	―	$22.02M	―	-75.39%	―	―	―
ILA	47 Neutral	AU$35.85M	―	-143.22%	―	―	-4.06%
AVE	46 Neutral	AU$14.28M	―	-64.72%	―	139.19%	33.33%
NOX	36 Underperform	AU$14.03M	―	-42.50%	―	―	80.96%

Starpharma Holdings Limited Corporate Events

Starpharma Announces Cessation of Performance Rights

Starpharma Holdings Limited announced the cessation of 716,375 performance rights due to unmet conditions, impacting its issued capital structure. This development may affect stakeholders’ perceptions of the company’s operational progress and could influence its market positioning by highlighting challenges in meeting performance targets.

Change in Substantial Holder’s Voting Power at Starpharma Holdings

Starpharma Holdings Limited has experienced a change in the interests of its substantial holder, UIL Limited, which has decreased its voting power from 8.02% to 6.39%. This change in voting power may impact the company’s governance dynamics and influence within the market, as substantial holders often have significant sway in decision-making processes.

Robmar Investments Alters Stake in Starpharma Holdings

Robmar Investments Pty Limited has filed a notice of change of interests, indicating a shift in its substantial holding in Starpharma Holdings Limited. This change could impact Starpharma’s shareholder dynamics and potentially influence its strategic decisions, reflecting broader market movements or shifts in investor confidence.

Starpharma Advances Strategic Initiatives and Expands Market Presence

Starpharma Holdings Limited has reported significant progress in its strategic initiatives, including advancing partnerships and developing its DEP® SN38 clinical program based on FDA feedback. The company has launched new products and campaigns in various regions, reaffirmed its strategic priorities, and is focusing on enhancing its radiopharmaceutical program. Despite challenges in the biotech sector, Starpharma remains committed to leveraging its dendrimer technology for value generation through partnerships and innovative asset development.